| Literature DB >> 36003522 |
Yue Ke1, Lei Huang1, Yu Song1, Zhenxin Liu1, Linshuang Liang1, Linmao Wang2, Taoyun Wang1.
Abstract
Ginseng (Panax ginseng) is a perennial herbaceous plant belonging to Panax genus of Araliaceae. Ginsenosides are a kind of important compounds in ginseng and minor ginsenosides are secondary metabolic derivatives of ginsenosides. Studies have shown that minor ginsenosides have many pharmacological effects, such as antioxidant, anti-tumor, anti-platelet aggregation, and neuroprotective effects. However, the therapeutic effects of minor ginsenosides are limited due to poor solubility in water, short half-life, and poor targeting accuracy. In recent years, to improve the application efficiency, the research on the nanocrystallization of minor ginsenosides have attracted extensive attention from researchers. This review focuses on the classification, preparation methods, pharmacological effects, and action mechanisms of minor ginsenoside nanoparticles, as well as existing problems and future direction of relevant research, which provides a reference for the in-depth research of minor ginsenoside nanoparticles.Entities:
Keywords: action mechanism; minor ginsenosides; nanoparticles; pharmacological effects; preparation
Year: 2022 PMID: 36003522 PMCID: PMC9393412 DOI: 10.3389/fphar.2022.974274
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.988
FIGURE 1Preparation process and cell uptake diagram.
Enhanced effect of minor ginsenoside nano drug delivery system on minor ginsenoside.
| Minor ginsenoside types | Type of drug carriers | Enhanced effects of nano-drug delivery system | References |
|---|---|---|---|
| CK | Liposomes | Improving encapsulation efficiency; enhanced uptake efficiency and cytotoxicity of A549 cells |
|
| Liposomes | Increase drug solubility; increased tumor targeting; enhancement of anti-tumor effect |
| |
| Micelles | Enhanced the cytotoxicity of HepG2 and Huh-7 cells |
| |
| Micelles | Cytotoxicity to A549 cells; increased tumor targeting |
| |
| Micelles | Improved CK water solubility; promoted tumor cell apoptosis, inhibited tumor cell invasion, metastasis and efflux; increased tumor targeting |
| |
| Chitosan-based nanoparticles | Improved CK water solubility; anti-proliferation effect on HepG2 cells; greater cytotoxicity and higher apoptosis rate |
| |
| Chitosan-based nanoparticles | Enhanced uptake efficiency and cytotoxicity of PC3 cells |
| |
| Chitosan-based nanoparticles | Improved CK water solubility; higher cytotoxicity to HT29 and HepG2 cells |
| |
| Albumin-based nanoparticles | Improved CK water solubility; higher toxicity to cancer cells; enhanced anti-inflammatory effect |
| |
| Gold nanoparticles | Slightly high cytotoxicity to A549 and HT29 cells; increased apoptosis of cancer cells |
| |
| Mesoporous silicas | Good biocompatibility to normal cell line ( HaCaT skin cells ); higher cytotoxicity to A549, HepG2 and HT29 cell lines; better anti-inflammatory effect on RAW264.7 cells |
| |
| Rg3 | Liposomes | Increased uptake, antiproliferative and targeting of glioma spheres |
|
| Liposomes | More pronounced sustained release |
| |
| Liposomes | Improved the bioavailability; enhanced cytotoxicity ; inhibited angiogenesis and growth of lung cancer |
| |
| Liposomes | Enhanced inhibition of tumor cell proliferation |
| |
| Liposomes | Enhanced inhibition of tumor cell proliferation; Increased tumor targeting |
| |
| Liposomes | Enhance the inhibitory efficiency on HepG2 cells and HUVEC cells; increased cellular uptake |
| |
| Liposomes | Inhibition of A375 melanoma cells |
| |
| Microemulsions | Microemulsion with optimum physical and chemical stability |
| |
| Microemulsions | Controlled drug release |
| |
| Micelles | Inhibition of tumor angiogenesis |
| |
| Micelles | Improved water solubility and bioavailability of Rg3; reduced adriamycin - induced cardiotoxicity and enhanced its anticancer effect |
| |
| Polymer-based nanoparticles | Improved cardiac function and reduced infarct size |
| |
| Polymer-based nanoparticles | Targeted cancer cells ; significantly inhibited tumor proliferation; circulated in blood longer |
| |
| Polymer-based nanoparticles | Sustained drug release; inhibited the proliferation of A431 cancer cells and induced apoptosis |
| |
| Polymer-based nanoparticles | More easily through the blood brain barrier; inhibition of proliferation of C6 glioma cells |
| |
| Polymer-based nanoparticles | Sustained drug release and delivery |
| |
| Polymer-based nanoparticles | Sustained drug release |
| |
| Polymer-based nanoparticles | Drug release regulated with temperature; inhibitory effect on HepG2 hepatoma cells |
| |
| Polymer-based nanoparticles | Inhibited tumor angiogenesis ; sustained drug release |
| |
| Polymer-based nanoparticles | Improved antitumor activity |
| |
| Polymer-based nanoparticles | Sustained drug release; Improved anti-angiogenic activity |
| |
| Chitosan-based nanoparticles | Sustained drug release; higher fatigue resistance |
| |
| Albumin-based nanoparticles | Higher antitumor activity in HepG2 and A549 cells |
| |
| Albumin-based nanoparticles | Sustained drug release; inhibitory effect on proliferation of A549 cells |
| |
| Albumin-based nanoparticles | Sustained drug release; inhibitory effect on Hela cells of cervical cancer |
| |
| Gold nanoparticles | Improved Rg3 water solubility |
| |
| Gold nanoparticles | Enhanced anti-inflammatory effect |
| |
| Mesoporous silicas | Inhibited the proliferation of A549 cells; improved drug dissolution rate |
| |
| Magnetic nanoparticles | Nontoxic safety; automatic targeting of mouse liver |
| |
| Magnetic nanoparticles | Sustained drug release; inhibition of HeLa cell proliferation |
| |
| Composite nano carriers | Sustained drug release; improved cell uptake efficiency |
| |
| Nanofibers | Higher inhibitory effect on hypertrophic scar formation |
| |
| Rg5 | Liposomes | Tumor targeting; inhibited tumor growth |
|
| Liposomes | Tumor targeting; inhibited tumor growth |
| |
| Albumin-based nanoparticles | Inhibited tumor growth |
| |
| Rh1 | Liposomes | Improved encapsulation efficiency and solubility |
|
| Self - microemulsions | Enhanced intestinal cellular uptake and oral utilization |
| |
| Polymer-based nanoparticles | Increased cytotoxicity to lung cancer |
| |
| Rh2 | Liposomes | Sustained drug release; enhanced uptake and cytotoxicity of PC3 cells |
|
| Liposomes | Extended blood circulation; inhibited tumor growth |
| |
| Liposomes | Higher inhibitory activity against HepG2 xenografts |
| |
| Microemulsions | Inhibited the growth of A549 tumor xenografts |
| |
| Microemulsions | Accumulation in tumors; improved antitumor effect |
| |
| Self - microemulsions | Enhanced intestinal cellular uptake and oral utilization |
| |
| Micelles | Improved Rh2 water solubility; enhanced drug uptake; extended drug retention; improved antitumor effect |
| |
| Micelles | Increased cell uptake; inhibited the proliferation of A549 cells; longer blood retention period |
| |
| Micelles | Increased solubility; inhibited tumor growth |
| |
| Polymer-based nanoparticles | Increased cytotoxicity to lung cancer |
| |
| Polymer-based nanoparticles | Sustained drug release; increased the residence time of drugs in inflammatory tissues |
| |
| Polymer-based nanoparticles | Increased solubility; longer circulation time; improved antitumor effect |
| |
| Polymer-based nanoparticles | Increased solubility; sustained drug release; increased inhibition of glioma cell proliferation; improved antitumor effect |
| |
| Chitosan-based nanoparticles | Higher cytotoxicity to A549 cells |
| |
| Albumin-based nanoparticles | Improved water solubility; enhanced the anticancer effect on A549 lung cancer cells and HT29 colon cancer cells; higher anti-inflammatory ability |
| |
| Mesoporous silicas | Good biocompatibility to normal cell line ( HaCaT skin cells ); higher cytotoxicity to A549, HepG2 and HT29 cell lines; better anti-inflammatory effect on RAW264.7 cells |
| |
| Graphene-based nanoparticles | Higher antitumor activity; reduced toxicity to the coagulation system and heart tissue |
| |
| Graphene-based nanoparticles | Higher anticancer activity; reduced side effects on normal cells ( red blood cells, heart tissue, etc. ) |
|
FIGURE 2Main action mechanism: Passive targeting (A); Active targeting (B).
FIGURE 3Minor ginsenoside liposome drug delivery system and mechanism of tumor-targeted therapy.
FIGURE 4Structure and functions of micelles.
FIGURE 5Preparation and action mechanism of Rg3-NPs.
FIGURE 6Self-assembly process of chitosan nanoparticles loaded with minor ginsenoside CK (Zhang et al., 2018).
FIGURE 7Schematic diagram of endocytosis mechanism and photothermal therapy (Kim et al., 2019).
FIGURE 8Structure of mesoporous silica nanoparticles (Singh et al., 2017c).
FIGURE 9Functional principle of carbon nanotubes (Bianco et al., 2005).